BINOCRIT 4000 IU/0.4ml Price

Overview

Welcome to Dwaey, specifically on BINOCRIT 4000 IU/0.4ml Injection/Solution for page.
This medicine contains an important and useful components, as it consists of Epoetin alfa (Recombinant Human Erythropoietin).
BINOCRIT 4000 IU/0.4ml is available in the market in concentration 4000 IU/Syringe and in the form of Injection/Solution for.

SANDOZ GMBH is the producer of BINOCRIT 4000 IU/0.4ml and it is imported from AUSTRIA, The most popular alternatives of BINOCRIT 4000 IU/0.4ml are listed downward .

Mode Of Action

Epoetin alfa stimulates the differentiation and proliferation of erythroid precursors, release of reticulocytes into the circulation and synthesis of cellular Hb thus regulating erythropoiesis.

Indication

• Anaemia of chronic renal failure
• Anaemia in zidovudine-treated HIV-infected patients
• Anemia related to non-myeloid malignant disease chemotherapy
• To reduce the need for allogenic blood tranfusion
• Anaemia of prematurity.

Precaution

Hypertension; history of seizures; thrombocytosis; chronic liver failure; poor renal function; ischaemic vascular disease; malignant tumours. Increased risk of thrombotic events. Monitor BP during treatment. Regularly monitor platelet counts and serum-potassium concentration. Iron deficiency, infection or inflammatory disorders, haemolysis, or aluminium intoxication will reduce efficacy. Proper dosage control is required to prevent to rapid increase in the haematocrit and haemoglobin levels. Pregnancy; lactation. Lactation: Unknown whether drug is excreted in breast milk; use with caution; avoid administering multidose vials

Side Effects

• >10% Pyrexia (10-42%)
• Nausea (11-35%)
• Hypertension (14-27%)
• Cough (4-26%)
• Vomiting (12-28%)
• Pruritus (12-21%)
• Rash (2-19%)
• Headache (5-18%)
• Arthralgias (10-16%) 1-10% Arthralgia (10%)
• Myalgia (10%)
• Stomatitis (10%)
• Diarrhea (9%)
• Dizziness (9%)
• Edema (9%)
• Fatigue (9%)
• Weight decrease (9%)
• Medical device malfunction (artificial kidney clotting during dialysis) (8%)
• Vascular occlusion (vascular access thrombosis) (8%)
• Vomiting (8%)
• Asthenia (7%)
• Chest pain (7%)
• Injection-site irritation (7%)
• Muscle spasm (7%)
• Upper respiratory tract infection (URTI) (7%)
• Urticaria (3%)
• Seizures (2.5%)
• Pulmonary embolism (1%)
• Respiratory tract congestion (1%)

Contra indication

Hypersensitivity to albumin (human) or mammalian cell-derived products; uncontrolled hypertension.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks